Citation, DOI, disclosures and article data
At the time the article was created Frank Gaillard had no recorded disclosures.View Frank Gaillard's current disclosures
At the time the article was last revised Frank Gaillard had the following disclosures:
- Radiopaedia Australia Pty Ltd and Radiopaedia Events Pty Ltd, Director, Founder and CEO (Radiopaedia) (ongoing)
- Biogen Australia Pty Ltd, Investigator-Initiated Research Grant for CAD software in multiple sclerosis: finished Oct 2021 (past)
These were assessed during peer review and were determined to not be relevant to the changes that were made.View Frank Gaillard's current disclosures
Subependymomas are uncommon, benign (WHO grade 1) tumors which are slow-growing and non-invasive. They tend to occur in middle-aged and older individuals and usually identified as an incidental finding.
These tumors were previously also known as subependymal astrocytomas, not to be confused with subependymal giant cell astrocytomas, which are both seen in association with tuberous sclerosis. They are also considered by some to be variants of ependymomas, with which they may co-exist (see below).
Subependymomas tend to present in middle-aged to older individuals (typically 5th to 6th decades 3). There is a slight male predilection (M:F 2.3:1) 6,8. Rarely there is a genetic predisposition for these tumors 8.
Typically patients are asymptomatic and small lesions are discovered incidentally. In some cases, especially when the tumors are larger, presentation is with symptoms of raised intracranial pressure due to obstructive hydrocephalus.
Subependymomas are sharply demarcated nodules, usually no more than 2 cm in diameter, arising from the ependyma by a narrow pedicle 6,8. Size is the most important distinguishing feature compared to subependymal giant cell astrocytoma.
The histopathology of subependymomas is distinct comprising of a tumor arising from the subependymal glial layer with low cellularity and no high-grade features (no mitoses, Ki-67/MIBI index <1.5%, no necrosis). These lesions are hypovascular. Loose perivascular pseudorosettes are occasionally seen. They are a WHO grade 1 tumor (see WHO classification of CNS tumors) 8.
Occasionally foci of cellular ependymoma are seen, although the effect on clinical behavior is unclear 4-5. They are graded according to the ependymoma component and not surprisingly behave similarly to the higher grade (ependymoma) component 6,8.
Subependymomas are most commonly seen in the fourth ventricle, but can arise anywhere where there is ependyma. They are therefore in the differential for other intraventricular masses. Distribution in the ventricular system is as follows 6,8:
- fourth ventricle: 50-60%
- lateral ventricles (usually frontal horns): 30-40%
- third ventricle: rare
- central canal of the spinal cord: rare
They are usually small, typically less than 1-2 cm in size 6.
Isodense to somewhat hypodense intraventricular mass compared to adjacent brain, which does not usually enhance. If large it may have cystic or even calcific components (seen in up to half of cases 3). Surrounding vasogenic edema is usually absent.
- iso-hypointense to white matter
- generally homogeneous but may be heterogeneous in larger lesions
- hyperintense to adjacent white and grey matter
- again heterogeneity may be seen in larger lesions, occasionally with susceptibility related signal dropout due to calcifications
- no adjacent parenchymal edema (as no brain invasion is present) 6
T1 C+ (Gd)
- usually no enhancement, although at times may demonstrate mild enhancement
As expected from the histology, subependymomas show no or little vascularity 6.
Treatment and prognosis
If appearances are characteristic and the patient is asymptomatic, then follow up is a viable option.
Resection should be considered if the patient is symptomatic (hydrocephalus or mass effect), the mass has an atypical appearance or demonstrates growth. Local resection is curative and even debulking has an excellent outcome 8.
General imaging differential considerations include other intraventricular neoplasms and lesions. A few specific lesions to consider include:
- usually in children, or younger adults
- heterogeneous enhancement
choroid plexus papilloma
- vividly enhancing
- usually in children, or younger adults
- in adults more common in the 4th ventricle
- particularly if close to the septum pellucidum
- overall less common
- typically seen in younger patients (20-40 years of age)
ring-shaped lateral ventricular nodules
- small lesions with a diameter < 10 mm
subependymal giant cell astrocytomas and subependymal nodules
- seen almost exclusively in patients with tuberous sclerosis
- 1. Ragel B, Osborn A, Whang K, Townsend J, Jensen R, Couldwell W. Subependymomas: An Analysis of Clinical and Imaging Features. Neurosurgery. 2006;58(5):881-90; discussion 881. doi:10.1227/01.NEU.0000209928.04532.09 - Pubmed
- 2. Russell J, Gaillard F, Drummond K. A Mass in the Fourth Ventricle. J Clin Neurosci. 2009;16(3):425, 482. - Pubmed
- 3. Koral K, Kedzierski R, Gimi B, Gomez A, Rollins N. Subependymoma of the Cerebellopontine Angle and Prepontine Cistern in a 15-Year-Old Adolescent Boy. AJNR Am J Neuroradiol. 2008;29(1):190-1. doi:10.3174/ajnr.A0821 - Pubmed
- 4. Tonn J, Westphal M, Rutka J. Oncology of CNS Tumors. (2010) ISBN: 9783642028731 - Google Books
- 5. Keating R, Goodrich J, Packer R. Tumors of the Pediatric Central Nervous System. (2001) ISBN: 9780865778481 - Google Books
- 6. Smith A, Smirniotopoulos J, Horkanyne-Szakaly I. From the Radiologic Pathology Archives: Intraventricular Neoplasms: Radiologic-Pathologic Correlation. Radiographics. 2013;33(1):21-43. doi:10.1148/rg.331125192 - Pubmed
- 7. Chiechi M, Smirniotopoulos J, Jones R. Intracranial Subependymomas: CT and MR Imaging Features in 24 Cases. AJR Am J Roentgenol. 1995;165(5):1245-50. doi:10.2214/ajr.165.5.7572512 - Pubmed
- 8. International Agency for Research on Cancer, Otmar D. Wiestler. WHO Classification of Tumours of the Central Nervous System. (2016) ISBN: 9789283244929 - Google Books